Compare

Alnylam Pharmaceuticals, Inc. vs Jazz Pharmaceuticals plc vs BioMarin Pharmaceutical Inc vs United Therapeutics Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Alnylam Pharmaceuticals, Inc. ALNY	Jazz Pharmaceuticals plc JAZZ	BioMarin Pharmaceutical Inc BMRN	United Therapeutics Corp UTHR
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$3.71B	$4.27B	$3.22B	$3.18B
Revenue growth (YoY)	+65.2%	+4.9%	+12.9%	+10.6%
Gross margin	81.8% (computed)	n/a	77.7% (computed)	87.9% (computed)
Operating margin	13.5%	-10.1%	12.7%	46.9%
Net margin	8.4%	-8.3%	10.8%	41.9%
Net income	$313.75M	-$356.15M	$348.90M	$1.33B
EPS (Diluted)	$2.33	-$5.84	$1.80	$27.86
Operating cash flow	$524.08M	$1.36B	$827.99M	$1.56B
Free cash flow	$465.38M	$1.30B	$724.96M	$1.04B
Cash & equivalents	$1.66B	$1.39B	$1.31B	$1.56B
Total assets	$4.97B	$11.66B	$7.59B	$7.88B
Total liabilities	$4.18B	n/a	$1.51B	$783.80M
Shareholders' equity	$789.18M	$4.32B	$6.09B	$7.10B
Return on year-end equity	39.8%	-8.2%	5.7%	18.8%
Shares outstanding	132.38M	61.44M	192.30M	43.64M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Alnylam Pharmaceuticals, Inc.	Jazz Pharmaceuticals plc	BioMarin Pharmaceutical Inc	United Therapeutics Corp
Latest	$3.71B Ended 2025-12-31	$4.27B Ended 2025-12-31	$3.22B Ended 2025-12-31	$3.18B Ended 2025-12-31
1 year earlier	$2.25B Ended 2024-12-31	$4.07B Ended 2024-12-31	$2.85B Ended 2024-12-31	$2.88B Ended 2024-12-31
2 years earlier	$1.83B Ended 2023-12-31	$3.83B Ended 2023-12-31	$2.42B Ended 2023-12-31	$2.33B Ended 2023-12-31
3 years earlier	$1.04B Ended 2022-12-31	$3.66B Ended 2022-12-31	$2.10B Ended 2022-12-31	$1.94B Ended 2022-12-31
4 years earlier	$844.29M Ended 2021-12-31	$3.09B Ended 2021-12-31	$1.85B Ended 2021-12-31	$1.69B Ended 2021-12-31